Assessing and addressing barriers to IPT2 uptake in Uganda

Malaria in pregnancy (MIP) poses substantial risks to mother, foetus and newborn child

• From: Department for International Development
• Published: 1 March 2017

• Country: Uganda
• Document Type: Research Paper
• Theme: Health
• Authors: Rassi, C, Siduda, Dr Sam, Graham, Dr Kirstie, Meler, J, et al

Abstract

Malaria in pregnancy (MIP) poses substantial risks to mother, foetus and newborn child. The World Health Organization (WHO) recommends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) in areas of moderate or high transmission as one of three strategies for the prevention and control of MIP. IPTp is typically provided as part of the focused antenatal care model (ANC), which stipulates that pregnant women should have at least four ANC assessments at specified intervals.

This research is supported by the Department for International Development’s COMDIS–HSD Programme which is led by the University of Leeds

Citation

Christian Rassi, Dr Sam Gudoi Siduda, Dr Kirstie Graham, Joslyn Meier, et al. Assessing and addressing barriers to IPT2 uptake in Uganda. COMDIS-HSD Research Brief (2017) 4p

Links

Assessing and addressing barriers to IPT2 uptake in Uganda

Published 1 March 2017